The outcome of combination immunotherapy using anti-VISTA plus anti-PD-L1 or anti-PD-1 antibodies increased TNFα, IFNγ, and serine protease such as granzyme B (GrzB) in CD8+ T lymphocytes and decreased the tumor growth [129]. The gene discussed is PDCD1; the disease is neoplasm.